Velocity Clinical Research is now a Society for Clinical Research Sites (SCRS) Global Impact Partnership (GIP). Paul Evans, PhD, President and CEO of Velocity, said the company is excited to leverage this partnership to further improve clinical research, both within Velocity and industry-wide. “The SCRS community can play an integral role in the way sites … Read more
Clinical trials — especially high-volume trials — are primarily designed to collect quantitative data. Collecting and reviewing qualitative data and experiential feedback from trial participants is rarely prioritized. Before being acquired by Velocity Clinical Research, Meridian Clinical Research built an in-house surveying system to elevate the participant’s voice. The system, which is largely automated, collects … Read more
Velocity Clinical Research (“Velocity”), the largest integrated research site organisation globally, today announces it has strengthened its European senior executive team with three strategic hires, as the firm continues its expansion in the region. Évelyne Newton joins as Vice President of Business Development, Sandra Stark is Vice President of European Operations and Maria Lehretz is … Read more
1: Consolidation and scale of the market It is well known that fragmentation of the clinical sites business has been identified as a market opportunity by private equity firms. As a result of a PE capital injection, there has been increased merger and acquisition activity within the sector, leading to a level of consolidation that … Read more
Brandon Essink, MD, CPI, was the lead author of the article, “The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials”. Dr. Essink oversaw two phase 1 studies that evaluated the safety and immunogenicity of … Read more
DURHAM, N.C., July 27, 2022 /PRNewswire/ — Velocity Clinical Research (“Velocity”), the leading integrated research site organisation, today announces it has acquired its first European site, Clinical Research Hamburg, in Germany for an undisclosed amount. The acquisition is the first in a series of deals lined up across the UK and Germany, as the company grows its network of integrated … Read more
Velocity Clinical Research (“Velocity”), the leading integrated research site organization, today announces its acquisition of Meridian Clinical Research for an undisclosed amount. The deal makes Velocity the largest dedicated research site organization in the world with approximately 80 sites in the U.S. and Europe, including a tech hub in Hyderabad, India. Meridian is a multi-specialty … Read more
In 2022 Velocity undertook its first national survey in the U.S. of patients who have previously taken part in clinical research, receiving 1,129 responses. We wanted to gauge views and attitudes on taking part in clinical research, including thoughts regarding decentralization and the use of technology. The results led us to three key insights and … Read more
Velocity Clinical Research (“Velocity”), the leading integrated research site organization, today announces it has acquired MedPharmics, a multi-site company based in the US. The acquisition brings Velocity’s total number of locations to 40 sites across 19 U.S. states and Europe. With this acquisition, Velocity will add just over 100 employees of diversified backgrounds to the … Read more
Meridian Clinical Research, now part of Velocity Clinical Research, enrolled the first participant in Moderna’s Phase 1 clinical trial for an Epstein-Barr virus (EBV) vaccine candidate (mRNA-1189). Congratulations to Moderna, and to Brandon Essink, MD, CPI, and the team in Omaha, Nebraska! Read the Moderna press release >